ReviewFEMS microbiology reviews2021
In vitro infection models to study fungal-host interactions.
Review in FEMS microbiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Innovation in antifungal therapy.EMBO molecular medicine · 2026Review
- Using fluorescent in vitro amphibian cell infection models to quantify pathogenicity of Batrachochytrium dendrobatidis.Methods (San Diego, Calif.) · 2026Article
- Mesenchymal Stem Cells in Fungal Infections: Immunomodulation, Direct Antifungal Activity, and the Promise of the Secretome.Biomedicines · 2026Review
- DMEM and EMEM as alternate growth media for pathogenic Leptospira.PLoS neglected tropical diseases · 2026Article
- Host albumin redirects Candida albicans metabolism to engage an alternative pathogenicity pathway.Nature communications · 2025Article
- Impact of Clove Essential Oil on the Intestinal Flora in Mice Infected withMolecules (Basel, Switzerland) · 2025Article
- DMEM and EMEM are suitable surrogate media to mimic host environment and expand leptospiral pathogenesis studies usingbioRxiv : the preprint server for biology · 2025Article
- Isavuconazole in the treatment of acute invasive fungal sinusitis: two case reports and literature review.Frontiers in medicine · 2025Article
- Molecular mechanisms of neutrophil regulatory network in anti-Candida infection.Frontiers in immunology · 2025Review
- Shining a light onmSphere · 2024Article
- Integrated multi-omics identifies pathways governing interspecies interaction between A. fumigatus and K. pneumoniae.Communications biology · 2024Article
- Candida albicans translocation through the intestinal epithelial barrier is promoted by fungal zinc acquisition and limited by NFκB-mediated barrier protection.PLoS pathogens · 2024Article
- Novel methodologies for host-microbe interactions and microbiome-targeted therapeutics in 3D organotypic skin models.Microbiome · 2023Article
- Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections.Open biology · 2023Review
- The Candida glabrata Parent Strain Trap: How Phenotypic Diversity Affects Metabolic Fitness and Host Interactions.Microbiology spectrum · 2023Article
- The Impact of Corticosteroids on the Outcome of Fungal Disease: a Systematic Review and Meta-analysis.Current fungal infection reports · 2023Review
- Essential Oil and Supercritical Carbon Dioxide Extract of Grapefruit Peels Formulated forACS omega · 2022Article
- Review
- InfectionCMA: A Cell MicroArray Approach for Efficient Biomarker Screening in In Vitro Infection Assays.Pathogens (Basel, Switzerland) · 2022Article
- Current Models to Study theFrontiers in fungal biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Fungal infections (mycoses) affect over a billion people per year. Approximately, two million of these infections are life-threatening, especially for patients with a compromised immune system. Fungi of the genera Aspergillus, Candida, Histoplasma and Cryptococcus are opportunistic pathogens that contribute to a substantial number of mycoses. To optimize the diagnosis and treatment of mycoses, we need to understand the complex fungal-host interplay during pathogenesis, the fungal attributes causing virulence and how the host resists infection via immunological defenses. In vitro models can be used to mimic fungal infections of various tissues and organs and the corresponding immune responses at near-physiological conditions. Furthermore, models can include fungal interactions with the host-microbiota to mimic the in vivo situation on skin and mucosal surfaces. This article reviews currently used in vitro models of fungal infections ranging from cell monolayers to microfluidic 3D organ-on-chip (OOC) platforms. We also discuss how OOC models can expand the toolbox for investigating interactions of fungi and their human hosts in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.